<DOC>
	<DOCNO>NCT01721265</DOCNO>
	<brief_summary>All subject study previously Idenix HCV study receive study drug 3 consecutive day . Subjects receive placebo previous Idenix study enrol study . In study , researcher try find answers question : - How much ( ) hepatitis C virus blood stop Idenix study drug ? - Is hepatitis C virus possibly resistant treatment Idenix study drug similar drug ?</brief_summary>
	<brief_title>3-Year Observational Virology Follow-up Study Subjects Who Participated Studies Idenix Anti-HCV , Direct Acting Antivirals</brief_title>
	<detailed_description>The data obtain study use understand long-term efficacy Idenix DAAs use treat HCV infection understand HCV resistance Idenix DAAs .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Read sign write informed consent form ( ICF ) nature study fully explain Have participate Idenixsponsored study Idenix DAA Received least 3 consecutive day DAA treatment Idenixsponsored study Agreed comply visit schedule laboratory test Treatment placebo , Idenix sponsor study Antiviral treatment HCV participation Idenix sponsor study Idenix DAA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>IDX184</keyword>
	<keyword>IDX719</keyword>
</DOC>